(#48) Treatment Patterns and Healthcare Resource Utilization Among Patients Receiving the Long-Acting Injectable Antipsychotic TV-46000 Versus Second-Generation Oral Antipsychotics

Abstract: Background: Long-acting injectable antipsychotics (LAIs) have been associated with improved adherence and outcomes when compared with oral antipsychotics (OAs). This study aimed to compare healthcare resource utilization (HCRU) with TV-46000, a long-acting injectable form of risperidone, versus second-generation OAs (SGOAs) in adults with schizophrenia. Methods: Patients in the Kythera closed claims database aged ?18 years with schizophrenia who were continuously enrolled in Medicaid, Medicare, or commercial health plans for a 2-year baseline period and a 6-month follow-up period after being prescribed TV-46000 or an SGOA were included (study period: May 1, 2021ñOct 31, 2024). Patients were propensity-score matched based on demographic and medical history variables. Results: Among TV-46000ñtreated (n=720) versus SGOA-treated (n=720) patients, higher rates of adherence (defined as medication possession ratio ?0.8; 71.3% vs 52.8%, PShort Description: This retrospective cohort claims database study evaluated differences in treatment patterns and healthcare resource utilization (HCRU) among adult patients with schizophrenia who received the long-acting injectable antipsychotic medication TV-46000 q1m or q2m versus those who received second-generation oral antipsychotics (SGOAs). Regardless of dosing frequency, patients who received TV-46000 demonstrated higher adherence and persistence, fewer inpatient, outpatient, and ED visits, shorter hospital stays, and lower all-cause HCRU costs than those who received SGOAs or oral risperidone.Name of Sponsoring Organization(s): Teva Branded Pharmaceutical Products, R&D LLC.